OraSure Announces $40 Million Stock Repurchase Program
OraSure Technologies (NASDAQ: OSUR) has announced a significant stock repurchase program authorized by its Board of Directors. The program allows for the repurchase of up to $40 million of common stock over a 24-month period, to be funded from cash on hand.
The company, which specializes in point-of-need and home diagnostic tests and sample management solutions, will implement the repurchase through various methods in compliance with securities laws. Management retains discretion over the amount and timing of share repurchases, with the ability to modify, suspend, or discontinue the program without prior notice.
OraSure Technologies (NASDAQ: OSUR) ha annunciato un significativo programma di riacquisto di azioni autorizzato dal suo Consiglio di Amministrazione. Il programma consente il riacquisto di fino a 40 milioni di dollari di azioni ordinarie nell'arco di 24 mesi, finanziato con liquidità disponibile.
L'azienda, specializzata in test diagnostici al punto di utilizzo e a casa, nonché in soluzioni di gestione dei campioni, attuerà il riacquisto attraverso vari metodi in conformità con le leggi sui titoli. La direzione mantiene la discrezione sull'importo e il momento dei riacquisti di azioni, con la possibilità di modificare, sospendere o interrompere il programma senza preavviso.
OraSure Technologies (NASDAQ: OSUR) ha anunciado un importante programa de recompra de acciones autorizado por su Junta Directiva. El programa permite la recompra de hasta 40 millones de dólares de acciones ordinarias durante un período de 24 meses, que se financiará con efectivo disponible.
La empresa, que se especializa en pruebas diagnósticas en el punto de atención y en el hogar, así como en soluciones de gestión de muestras, llevará a cabo la recompra a través de diversos métodos en cumplimiento con las leyes de valores. La dirección mantiene la discreción sobre la cantidad y el momento de las recompras de acciones, con la capacidad de modificar, suspender o interrumpir el programa sin previo aviso.
오라세어 테크놀로지스 (NASDAQ: OSUR)는 이사회의 승인을 받은 중요한 자사주 매입 프로그램을 발표했습니다. 이 프로그램은 4천만 달러까지의 보통주를 24개월 동안 매입할 수 있도록 하며, 보유 현금으로 자금을 조달합니다.
이 회사는 필요 시점 및 가정에서의 진단 테스트와 샘플 관리 솔루션을 전문으로 하며, 증권법을 준수하여 다양한 방법으로 매입을 시행할 것입니다. 경영진은 주식 매입의 금액과 시기에 대한 재량권을 보유하며, 사전 통보 없이 프로그램을 수정, 중단 또는 종료할 수 있는 능력을 가지고 있습니다.
OraSure Technologies (NASDAQ: OSUR) a annoncé un programme de rachat d'actions significatif autorisé par son conseil d'administration. Le programme permet le rachat de jusqu'à 40 millions de dollars d'actions ordinaires sur une période de 24 mois, financé par des liquidités disponibles.
L'entreprise, spécialisée dans les tests diagnostiques au point de besoin et à domicile ainsi que dans les solutions de gestion des échantillons, mettra en œuvre le rachat par divers moyens en conformité avec les lois sur les valeurs mobilières. La direction conserve la discrétion quant au montant et au moment des rachats d'actions, avec la possibilité de modifier, suspendre ou interrompre le programme sans préavis.
OraSure Technologies (NASDAQ: OSUR) hat ein bedeutendes Aktienrückkaufprogramm bekannt gegeben, das von seinem Vorstand genehmigt wurde. Das Programm erlaubt den Rückkauf von bis zu 40 Millionen Dollar an Stammaktien über einen 24-Monats-Zeitraum, finanziert aus verfügbaren liquiden Mitteln.
Das Unternehmen, das sich auf Diagnosetests am Point-of-Care und zu Hause sowie auf Probenmanagementlösungen spezialisiert hat, wird den Rückkauf durch verschiedene Methoden in Übereinstimmung mit den Wertpapiergesetzen durchführen. Das Management behält sich das Ermessen über die Höhe und den Zeitpunkt der Aktienrückkäufe vor und hat die Möglichkeit, das Programm jederzeit ohne vorherige Ankündigung zu ändern, auszusetzen oder einzustellen.
- Authorization of $40 million stock buyback program indicates strong cash position
- Share repurchase program likely to enhance shareholder value
- 24-month timeline provides flexibility in execution
- Program demonstrates management's confidence in company's financial health
- Use of cash reserves for buyback may reduce funds available for business operations or growth initiatives
BETHLEHEM, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that its Board of Directors has authorized the repurchase of up to
The Company may repurchase the shares through various methods in compliance with applicable state and federal securities laws. The amount and timing of share repurchases will be determined by Management at its discretion. The repurchase program may be modified, suspended, or discontinued at any time at the Company’s discretion without prior notice.
About OraSure Technologies, Inc.
OraSure Technologies, Inc. (“OraSure”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure, please visit www.orasure.com
Forward Looking Statements
This Press Release contains certain “forward-looking statements” within the meaning of the Federal securities laws, including with respect to the Stock Repurchase Plan and the factors that will impact the amount and timing of purchases, if any, thereunder. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to, changes in price and volume and the volatility of the Common Stock and the other risk factors disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the Company’s subsequent filings with the SEC. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
| Investor Contact: Jason Plagman VP, Investor Relations investorinfo@orasure.com | Media Contact: Amy Koch Director, Corporate Communications media@orasure.com |
FAQ
How much is OraSure's (OSUR) new stock buyback program worth?
What is the timeline for OraSure's (OSUR) stock repurchase program?
How will OraSure (OSUR) fund its $40 million share repurchase program?
Can OraSure (OSUR) modify or suspend its newly announced buyback program?
